Abstract
Blood platelets play a key role in normal hemostasis but also in atherothrombosis due to their ability of thrombus formation at site of a ruptured atherosclerotic plaque. Platelets are also involved in vascular inflammation due to interactions with endothelial cells, leukocytes, and smooth muscle cells that may result in an excessive fibroproliferative response after vessel dilatation. This review article describes both, the current status of standard anti-platelet drug therapy using acetylsalicylic acid, adenosine diphosphate or glycoprotein IIb-IIIa receptor antagonists in the prevention of cardiovascular events as well as drawbacks like non-responsiveness or increased bleeding rates leading to enhanced reintervention and transfusion rates, both responsible for adverse clinical outcomes after coronary interventions.
Keywords: Abciximab, acetylsalicylic acid, acute coronary syndromes, clopidogrel, fibrinogen receptor antagonists, platelet function, platelet receptor blockade, prasugrel, thienopyridines, thromboxane A2 receptor antagonists, thrombin receptor antagonists, vorapaxar
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Volume: 11 Issue: 1
Author(s): Susanne M. Picker
Affiliation:
Keywords: Abciximab, acetylsalicylic acid, acute coronary syndromes, clopidogrel, fibrinogen receptor antagonists, platelet function, platelet receptor blockade, prasugrel, thienopyridines, thromboxane A2 receptor antagonists, thrombin receptor antagonists, vorapaxar
Abstract: Blood platelets play a key role in normal hemostasis but also in atherothrombosis due to their ability of thrombus formation at site of a ruptured atherosclerotic plaque. Platelets are also involved in vascular inflammation due to interactions with endothelial cells, leukocytes, and smooth muscle cells that may result in an excessive fibroproliferative response after vessel dilatation. This review article describes both, the current status of standard anti-platelet drug therapy using acetylsalicylic acid, adenosine diphosphate or glycoprotein IIb-IIIa receptor antagonists in the prevention of cardiovascular events as well as drawbacks like non-responsiveness or increased bleeding rates leading to enhanced reintervention and transfusion rates, both responsible for adverse clinical outcomes after coronary interventions.
Export Options
About this article
Cite this article as:
M. Picker Susanne, Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (1) . https://dx.doi.org/10.2174/1871525711311010009
DOI https://dx.doi.org/10.2174/1871525711311010009 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Association between Serum Asymmetric Dimethylarginine and Coronary Atherosclerotic Plaque in an Asymptomatic Population
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Advancements in the Understanding of Paclitaxel Metabolism in Tissue Culture
Current Pharmaceutical Biotechnology Interleukin-1 and Occlusive Arterial Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options
Vascular Disease Prevention (Discontinued) Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients
Current Drug Safety Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Research Progress of the UPR Mechanism and its Effect on Improving Foreign Protein Expression
Protein & Peptide Letters Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Exercise and Ischemic Preconditioning
Current Cardiology Reviews High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part I: (Patho)-Physiology, Rationale and Perspective on Pulse Pressure Amplification
Current Pharmaceutical Design Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
Current Drug Targets Beta-Blockers are Associated with Decreased In-Hospital Mortality and Stroke in Acute Decompensated Heart Failure: Findings from a Retrospective Analysis of a 22-Year Registry in the Middle East (1991-2013)
Current Vascular Pharmacology Open Questions about Pulmonary Hypertension and Exercise Training: A Critical Review
Current Respiratory Medicine Reviews The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Standardization of QRS Duration Measurement and LBBB Criteria in CRT Trials and Clinical Practice
Current Cardiology Reviews